(VIANEWS) – TG Therapeutics (TGTX), Arthur J. Gallagher & Co. (AJG), Selective Insurance Group (SIGI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. TG Therapeutics (TGTX)
224.1% sales growth and 11.57% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.09.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 157.33. Meaning, the purchaser of the share is investing $157.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.57%.
Sales Growth
TG Therapeutics’s sales growth is 599.5% for the present quarter and 224.1% for the next.
2. Arthur J. Gallagher & Co. (AJG)
15.8% sales growth and 10.3% return on equity
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to entities and individuals worldwide. It operates in Brokerage and Risk Management segments. The Brokerage segment offers retail and wholesale insurance and reinsurance brokerage services; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; and acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverages to underwriting enterprises. This segment performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers services in the areas of insurance and reinsurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent brokers and consultants. It serves commercial, industrial, public, religious, and nonprofit entities, as well as underwriting enterprises. Arthur J. Gallagher & Co. was founded in 1927 and is headquartered in Rolling Meadows, Illinois.
Earnings Per Share
As for profitability, Arthur J. Gallagher & Co. has a trailing twelve months EPS of $4.43.
PE Ratio
Arthur J. Gallagher & Co. has a trailing twelve months price to earnings ratio of 52.95. Meaning, the purchaser of the share is investing $52.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.3%.
3. Selective Insurance Group (SIGI)
11.7% sales growth and 13.32% return on equity
Selective Insurance Group, Inc., together with its subsidiaries, provides insurance products and services in the United States. It operates through four segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. The company offers property insurance products, which covers the financial consequences of accidental loss of an insured's real property, personal property, and/or earnings due to the property's loss; and casualty insurance products that covers the financial consequences of employee injuries in the course of employment, and bodily injury and/or property damage to a third party, as well as flood insurance products. It also invests in fixed income investments and commercial mortgage loans, as well as equity securities and alternative investment portfolio. The company offers its insurance products and services to businesses, non-profit organizations, local government agencies, and individuals through independent retail agents and wholesale general agents. Selective Insurance Group, Inc. was founded in 1926 and is headquartered in Branchville, New Jersey.
Earnings Per Share
As for profitability, Selective Insurance Group has a trailing twelve months EPS of $5.84.
PE Ratio
Selective Insurance Group has a trailing twelve months price to earnings ratio of 17.33. Meaning, the purchaser of the share is investing $17.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.32%.
Moving Average
Selective Insurance Group’s value is below its 50-day moving average of $103.14 and under its 200-day moving average of $101.98.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.6%, now sitting on 4.23B for the twelve trailing months.
Yearly Top and Bottom Value
Selective Insurance Group’s stock is valued at $101.19 at 06:22 EST, below its 52-week high of $109.58 and way higher than its 52-week low of $91.99.
4. CBOE Holdings (CBOE)
10% sales growth and 20.44% return on equity
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, Europe and Asia Pacific, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities. This segment also offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The Europe and Asia Pacific segment offers pan-European listed equities and derivatives transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, CBOE Holdings has a trailing twelve months EPS of $7.14.
PE Ratio
CBOE Holdings has a trailing twelve months price to earnings ratio of 24.99. Meaning, the purchaser of the share is investing $24.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.44%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 3.77B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 28, 2024, the estimated forward annual dividend rate is 2.2 and the estimated forward annual dividend yield is 1.23%.
Yearly Top and Bottom Value
CBOE Holdings’s stock is valued at $178.40 at 06:22 EST, way under its 52-week high of $199.00 and way higher than its 52-week low of $130.92.
Moving Average
CBOE Holdings’s value is below its 50-day moving average of $183.86 and above its 200-day moving average of $169.77.
5. Installed Building Products (IBP)
8.1% sales growth and 41.88% return on equity
Installed Building Products, Inc., together with its subsidiaries, engages in the installation of insulation, waterproofing, fire-stopping, fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving and mirrors, and other products in the continental United States. The company offers a range of insulation materials, such as fiberglass and cellulose, and spray foam insulation materials. It is also involved in the installation of insulation and sealant materials in various areas of a structure, which includes basement and crawl space, building envelope, attic, and acoustical applications. In addition, the company installs a range of caulk and sealant products that control air infiltration in residential and commercial buildings; and waterproofing options, including sheet and hot applied waterproofing membranes, as well as deck coating, bentonite, and air and vapor systems. It serves homebuilders, multi-family and commercial construction firms, individual homeowners, and repair and remodeling contractors through a network of approximately 210 branch locations. The company was formerly known as CCIB Holdco, Inc. Installed Building Products, Inc. was founded in 1977 and is based in Columbus, Ohio.
Earnings Per Share
As for profitability, Installed Building Products has a trailing twelve months EPS of $8.6.
PE Ratio
Installed Building Products has a trailing twelve months price to earnings ratio of 25.98. Meaning, the purchaser of the share is investing $25.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.88%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 0.63%.
6. Incyte Corporation (INCY)
7.5% sales growth and 12.5% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.
Moving Average
Incyte Corporation’s worth is under its 50-day moving average of $56.82 and below its 200-day moving average of $59.17.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 129.7% and 16.2%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.3%, now sitting on 3.7B for the twelve trailing months.
Sales Growth
Incyte Corporation’s sales growth is 7.9% for the current quarter and 7.5% for the next.
7. United Rentals (URI)
6.1% sales growth and 32.98% return on equity
United Rentals, Inc., through its subsidiaries, operates as an equipment rental company. It operates in two segments, General Rentals and Specialty. The General Rentals segment rents general construction and industrial equipment includes backhoes, skid-steer loaders, forklifts, earthmoving equipment, and material handling equipment; aerial work platforms, such as boom and scissor lifts; and general tools and light equipment comprising pressure washers, water pumps, and power tools for construction and industrial companies, manufacturers, utilities, municipalities, homeowners, and government entities. The specialty segment rents specialty construction products, including trench safety equipment consists of trench shields, aluminum hydraulic shoring systems, slide rails, crossing plates, construction lasers, and line testing equipment for underground work; power and heating, ventilating, and air conditioning equipment, such as portable diesel generators, electrical distribution equipment, and temperature control equipment; fluid solutions equipment for fluid containment, transfer, and treatment; and mobile storage equipment and modular office space. This segment serves construction companies involved in infrastructure projects, and municipalities and industrial companies. It also sells aerial lifts, reach forklifts, telehandlers, compressors, and generators; construction consumables, tools, small equipment, and safety supplies; and parts for equipment that is owned by its customers, as well as provides repair and maintenance services. The company sells used equipment through its sales force, brokers, website, at auctions, and directly to manufacturers. The company operates in the United States, Canada, Europe, Australia, and New Zealand. United Rentals, Inc. was incorporated in 1997 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, United Rentals has a trailing twelve months EPS of $35.31.
PE Ratio
United Rentals has a trailing twelve months price to earnings ratio of 19.11. Meaning, the purchaser of the share is investing $19.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.98%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 7, 2024, the estimated forward annual dividend rate is 6.52 and the estimated forward annual dividend yield is 0.94%.
Previous days news about United Rentals(URI)
- United rentals (uri) stock up on Q1 earnings & revenue beat. According to Zacks on Thursday, 25 April, "In March 2024, United Rentals acquired Yak, showcasing its strategy to expand its specialty rental business, enhance its one-stop-shop offerings, and leverage opportunities for both secular growth and cross-selling."
- Equipment rentals aids united rentals (uri) in Q1 earnings. According to Zacks on Friday, 26 April, "Nonetheless, margins in the core business remain healthy and Specialty gross margin, in particular, improved 200 bps from a year ago due to strong fixed cost absorption on higher revenues.(Read more: United Rentals Stock Up on Q1 Earnings & Revenue Beat)", "With a Zacks Rank #2 (Buy) and a consistent track record of surpassing earnings estimates, United Rentals demonstrates resilience and holds significant potential for growth. "
